Allarity Therapeutics (ALLR) Research & Development (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Research & Development came in at $1.3 million in Q1 2026, down 7.56% YoY from $1.4 million in Q1 2025, and down 22.52% on a QoQ basis from $1.7 million in Q4 2025.
Allarity Therapeutics (ALLR) Research & Development (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Research & Development data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Research & Development fell 7.56% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 21.88% YoY) and the FY2025 annual result came in at $6.6 million, up 8.28% from the prior year.
- Research & Development fell to $1.3 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.6 million in Q4 2022 to a low of $39000.0 in Q2 2022.
- A 5-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development plunged 89.23% — and 2024, when it surged 5464.1%.
- Tracing ALLR's Research & Development over 5 years: stood at $6.6 million in 2022, then sank by 60.19% to $2.6 million in 2023, then decreased by 29.58% to $1.8 million in 2024, then retreated by 9.37% to $1.7 million in 2025, then fell by 22.52% to $1.3 million in 2026.
- The last three Research & Development figures came in at $1.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - | 1.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 2.17 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 6.59 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 362,000.00 |
| Dec 31, 2021 | 9.52 Mn |
| Sep 30, 2021 | 190,000.00 |
| Jun 30, 2021 | 147,000.00 |